eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
9.31
-0.39 (-3.97%)
Aug 28, 2025, 4:00 PM - Market closed
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company.
The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025.
eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
eXoZymes, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Michael Heltzen |
Contact Details
Address: 750 Royal Oaks Drive, Suite 106 Monrovia, California 91016 United States | |
| Phone | 626 415 1488 |
| Website | exozymes.com |
Stock Details
| Ticker Symbol | EXOZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002010788 |
| ISIN Number | US4618741098 |
| Employer ID | 83-4550057 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Heltzen | President and Chief Executive Officer |
| Dr. Tyler Korman Ph.D. | Co-Founder and Vice President of Research |
| Dr. Paul Opgenorth Ph.D. | Co-Founder and Vice President of Development |
| Fouad Nawaz | Vice President of Finance |
| James U. Bowie Ph.D. | Founder and Independent Director |
| Lasse H. Gorlitz | Vice President of Communications |
| Michael Burns | Executive Vice President of Energy Transition |
| Dr. Zachary Karl Ph.D. | Vice President and Head of Business Development |
| Damien A. Perriman | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jul 28, 2025 | 8-K | Current Report |
| Jul 8, 2025 | 424B3 | Prospectus |
| Jul 8, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 23, 2025 | DEFR14A | Filing |
| Jun 20, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 20, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| Apr 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |